BNF for Children (BNFC) 2018-2019

▶Ciclosporinincreases the exposure tocolchicine. Avoid or
adjustcolchicinedose.rStudy
▶Cobicistatis predicted to increase the exposure tocolchicine.
Avoid potent inhibitors of CYP3A4 or adjustcolchicinedose.
rStudy
▶Crizotinibis predicted to increase the exposure tocolchicine.
Adjustcolchicinedose with moderate inhibitors of CYP3A4.
rStudy
▶Eliglustatis predicted to increase the exposure tocolchicine.
Avoid or adjustcolchicinedose.rTheoretical
▶Colchicineincreases the risk of rhabdomyolysis when given
withfibrates.rAnecdotal
▶HIV-protease inhibitorsare predicted to increase the exposure
tocolchicine. Avoid potent inhibitors of CYP3A4 or adjust
colchicinedose.rStudy
▶Idelalisibis predicted to increase the exposure tocolchicine.
Avoid potent inhibitors of CYP3A4 or adjustcolchicinedose.
rStudy
▶Imatinibis predicted to increase the exposure tocolchicine.
Adjustcolchicinedose with moderate inhibitors of CYP3A4.
rStudy
▶Lapatinibis predicted to increase the exposure tocolchicine.
Avoid or adjustcolchicinedose.oTheoretical
▶Macrolides(azithromycin)are predicted to increase the
exposure tocolchicine. Avoid or adjustcolchicinedose.r
Theoretical
▶Macrolides(clarithromycin)are predicted to increase the
exposure tocolchicine. Avoid potent inhibitors of CYP3A4 or
adjustcolchicinedose.rStudy
▶Macrolides(erythromycin)are predicted to increase the
exposure tocolchicine. Adjustcolchicinedose with moderate
inhibitors of CYP3A4.rStudy
▶Mirabegronis predicted to increase the exposure tocolchicine.
nTheoretical
▶Netupitantis predicted to increase the exposure tocolchicine.
Adjustcolchicinedose with moderate inhibitors of CYP3A4.
rStudy
▶Nilotinibis predicted to increase the exposure tocolchicine.
Adjustcolchicinedose with moderate inhibitors of CYP3A4.
rStudy
▶Ranolazineis predicted to increase the exposure tocolchicine.
Avoid or adjustcolchicinedose.rTheoretical
▶Rolapitantis predicted to increase the exposure tocolchicine.
oStudy
▶Colchicineincreases the risk of rhabdomyolysis when given
withstatins.rAnecdotal
▶Velpatasviris predicted to increase the exposure tocolchicine.
rTheoretical
▶Vemurafenibis predicted to increase the exposure to
colchicine. Avoid or adjustcolchicinedose.rTheoretical
Colecalciferol→see vitamin D substances
Colesevelam

SEPARATION OF ADMINISTRATIONManufacturer advises take

4 hours before, or after, other drugs.

Colestipol

SEPARATION OF ADMINISTRATIONManufacturer advises take

other drugs at least 1 hour before, or 4 hours after, colestipol.

Colestyramine

SEPARATION OF ADMINISTRATIONManufacturer advises take

other drugs at least 1 hour before, or 4–6 hours after,

colestyramine.

Colistimethate→seeTABLE 2p. 847 (nephrotoxicity),TABLE 20p. 851
(neuromuscular blocking effects)
Combined hormonal contraceptives
▶Combined hormonal contraceptivesare predicted to increase
the exposure toagomelatine.oStudy
▶Combined hormonal contraceptivesare predicted to increase
the exposure toaminophylline. Adjust dose.o
Theoretical
▶Combined hormonal contraceptivesare predicted to increase
the exposure toanagrelide.oTheoretical
▶Antiepileptics(carbamazepine, eslicarbazepine, fosphenytoin,
oxcarbazepine, perampanel, phenobarbital, phenytoin,

primidone, rufinamide, topiramate)are predicted to decrease

the efficacy ofcombined hormonal contraceptives. For FSRH

guidance, seeContraceptives, interactionsp. 497.rStudy

▶Combined hormonal contraceptivesalter the exposure to

antiepileptics(lamotrigine). Adjust dose.oStudy

▶Aprepitantis predicted to decrease the efficacy ofcombined

hormonal contraceptives. For FSRH guidance, see

Contraceptives, interactionsp. 497.rStudy

▶Bosentanis predicted to decrease the efficacy ofcombined

hormonal contraceptives. For FSRH guidance, see

Contraceptives, interactionsp. 497.rStudy

▶Oralcombined hormonal contraceptivespotentially decrease

the efficacy ofchenodeoxycholic acid. Avoid.o

Theoretical

▶Combined hormonal contraceptivesincrease the concentration

ofclozapine. Monitor side effects and adjust dose.rStudy

▶Cobicistatis predicted to decrease the efficacy ofcombined

hormonal contraceptives. Avoid.rStudy

▶Combined hormonal contraceptivesincrease the risk of raised

liver function tests when given withdasabuvir. Avoid.r

Study

▶Combined hormonal contraceptivesare predicted to increase

the exposure todopamine receptor agonists(ropinirole). Adjust

dose.oStudy

▶Efavirenzis predicted to decrease the efficacy ofcombined

hormonal contraceptives. For FSRH guidance, see

Contraceptives, interactionsp. 497.rStudy

▶Combined hormonal contraceptivesslightly increase the

exposure toerlotinib. Monitor side effects and adjust dose.

oStudy

▶Fosaprepitantis predicted to decrease the efficacy ofcombined

hormonal contraceptives. For FSRH guidance, see

Contraceptives, interactionsp. 497.rStudy

▶Griseofulvinpotentially decreases the efficacy ofcombined

hormonal contraceptives. For FSRH guidance, see

Contraceptives, interactionsp. 497.rAnecdotal

▶HIV-protease inhibitors(atazanavir)(unboosted) increase the

exposure tocombined hormonal contraceptives. Adjust dose.

rStudy

▶HIV-protease inhibitors(ritonavir)are predicted to decrease the

efficacy ofcombined hormonal contraceptives. For FSRH

guidance, seeContraceptives, interactionsp. 497.rStudy

▶Combined hormonal contraceptivesare predicted to increase

the risk of venous thromboembolism when given with

lenalidomide. Avoid.rTheoretical

▶Oralcombined hormonal contraceptivesslightly increase the

exposure tolomitapide. Separate administration by 12 hours.

oTheoretical

▶Combined hormonal contraceptivesare predicted to increase

the exposure toloxapine. Avoid.qTheoretical

▶Lumacaftoris predicted to decrease the efficacy ofcombined

hormonal contraceptives. Use additional contraceptive

precautions.rTheoretical

▶Combined hormonal contraceptivesare predicted to increase

the exposure tomelatonin.oTheoretical

▶Combined hormonal contraceptivesdecrease the effects of

metyrapone. Avoid.oTheoretical

▶Modafinilis predicted to decrease the efficacy ofcombined

hormonal contraceptives. For FSRH guidance, see

Contraceptives, interactionsp. 497.rStudy

▶Combined hormonal contraceptivesslightly increase the

exposure tomonoamine-oxidase B inhibitors(rasagiline).

oStudy

▶Combined hormonal contraceptivesincrease the exposure to

monoamine-oxidase B inhibitors(selegiline). Avoid.rStudy

▶Monoclonal antibodies(sarilumab)potentially decrease the

exposure tocombined hormonal contraceptives.r

Theoretical

▶Nevirapineis predicted to decrease the efficacy ofcombined

hormonal contraceptives. For FSRH guidance, see

Contraceptives, interactionsp. 497.rStudy

▶NSAIDs(etoricoxib)slightly increase the exposure tocombined

hormonal contraceptives.oStudy

BNFC 2018 – 2019 Colchicine—Combined hormonal contraceptives 901

Interactions

|Appendix 1

A1